Trial Profile
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 3389245A (Primary) ; Meningococcal vaccine group B OMV Novartis
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 24 Jul 2019 Results published in the Clinical Infectious Diseases
- 25 Apr 2017 Results assessing safety and immunogenicity, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 02 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.